Express Scripts Inc. et al.

2023 ME 68, 304 A.3d 239
CourtSupreme Judicial Court of Maine
DecidedNovember 7, 2023
DocketBCD-22-331
StatusPublished
Cited by1 cases

This text of 2023 ME 68 (Express Scripts Inc. et al.) is published on Counsel Stack Legal Research, covering Supreme Judicial Court of Maine primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Express Scripts Inc. et al., 2023 ME 68, 304 A.3d 239 (Me. 2023).

Opinion

MAINE SUPREME JUDICIAL COURT Reporter of Decisions Decision: 2023 ME 68 Docket: BCD-22-331 Argued: September 12, 2023 Decided: November 7, 2023 Revised: November 28, 2023

Panel: STANFILL, C.J., and MEAD, JABAR, HORTON, LAWRENCE, and DOUGLAS, JJ.

EXPRESS SCRIPTS INC. et al.

v.

STATE TAX ASSESSOR

JABAR, J.

[¶1] Express Scripts Inc. (ESI) and its unitary Maine affiliates

(collectively, Express Scripts) appeal from an order entered in the Business and

Consumer Docket (Duddy, J.) granting summary judgment approving the State

Tax Assessor’s method of calculating Express Scripts’ Maine tax liability. The

Assessor cross-appeals from the trial court’s (Murphy, J.) order sealing certain

aspects of the parties’ filings pursuant to Maine Rule of Civil Procedure 56, and

the trial court’s (Duddy, J.) subsequent order denying the Assessor’s motion to

unseal. We affirm the judgment and the challenged orders.

I. BACKGROUND

[¶2] During 2011, 2012, and 2013 (the Audit Period), ESI was a

corporation organized under Delaware law with its headquarters and executive 2

offices in St. Louis, Missouri. On April 2, 2012, Express Scripts Holding

Company, the parent company of ESI, acquired the stock of Medco Health

Solutions, Inc., and its affiliates. ESI and its affiliated entities were engaged

together in a unitary business that involved business activity both within and

outside Maine.1

[¶3] During the Audit Period, Express Scripts sold prescription drugs by

mail order delivery and provided infusion services throughout the United

States, including Maine. Additionally, Express Scripts sold claims adjudication

and other pharmacy benefit management (PBM) services throughout the

United States, including in Maine.2 During the Audit Period, Express Scripts

1“Unitary business” is defined by Maine statute as “a business activity which is characterized by unity of ownership, functional integration, centralization of management and economies of scale.” 36 M.R.S. § 5102(10-A) (2023); see also State Tax Assessor v. Kraft Foods Grp., Inc., 2020 ME 81, ¶¶ 19, 38, 42, 235 A.3d 837; Gannett Co. v. State Tax Assessor, 2008 ME 171, ¶¶ 12-13, 959 A.2d 741. “The unitary business concept ignores the separate legal existence of corporations . . . and focuses on such practical business realities as transfers of value among affiliated corporations.” Gannett, 2008 ME 171, ¶ 13, 959 A.2d 741; see Kraft, 2020 ME 81, ¶ 19, 235 A.3d 837. 2 Express Scripts repeatedly attempts to qualify or dispute the Assessor’s description of its business activities by asserting that what it sold was a “core bundle of services.” However, this phrase does not appear in any of Express Scripts’ PBM agreements, invoices, receipts, or any other record material. “[E]xtrinsic evidence is not admissible to explain or alter an unambiguous integrated contract.” Doe v. Lozano, 2022 ME 33, ¶ 17, 276 A.3d 44. The provisions of such contracts must be interpreted “according to [their] plain meaning.” Fortney & Weygandt, Inc. v. Lewiston DMEP IX, LLC, 2019 ME 175, ¶ 34, 222 A.3d 613 (quotation marks omitted). Thus, the affidavits submitted by Express Scripts in support of its “core bundle of services” argument would not be admissible as evidence to explain the contract and transactional material comprising much of the record. See M.R. Civ. P. 56(e). Therefore, Express Scripts’ “core bundle of services” argument has no factual support in the record, and to the extent that Express Scripts uses that phrase in its argument to attempt to create a genuine issue of material fact to survive a motion for summary judgment, the argument fails. 3

generated revenue primarily from the delivery of prescription drugs through

its contracted network of retail pharmacies, from home delivery of prescription

drugs, from specialty pharmacy services, and from services in its non-PBM

business segment. Revenues from the delivery of prescription drugs to Express

Scripts’ members represented 99.4% of revenues in 2011; 99.0% of revenues

in 2012; and 98.8% of revenues in 2013.

[¶4] Express Scripts’ “clients” during the Audit Period included health

insurers, health maintenance organizations, employers, governmental health

programs, and union-sponsored benefits plans. The clients’ “members” were

the primary recipients of Express Scripts’ services. If a client was a health

insurer, the term “members” referred to the insured individuals; if a client was

an employer, then the term “members” referred to the employees covered by

the employer’s health plan. The parties agree that, except for pricing, Express

Scripts’ agreements with its clients are substantially the same in all material

respects. Pursuant to written agreements with retail pharmacies that were in

effect during the Audit Period, Express Scripts negotiated the prices at which

retail pharmacies would provide prescription drugs to individual members and

managed national and regional networks that were responsive to client 4

preferences related to cost containment, convenience of access for members,

and network performance.

[¶5] When a member presented his or her Express Scripts identification

card at a retail pharmacy, Express Scripts communicated in real time with the

pharmacy to process prescription drug claims at the point of sale. The

pharmacist sent the member’s prescription information to Express Scripts

through its computer system, and Express Scripts processed the claim and

responded back to the pharmacist in real time. This process is referred to as

the “adjudication of claims.” The claims-adjudication process included Express

Scripts’ (A) confirming the member’s eligibility to the pharmacist;

(B) performing a concurrent drug interaction/utilization review;

(C) confirming to the retail pharmacy that it would receive payment from

Express Scripts pursuant to their agreements, if the claim was accepted; and

(D) informing the retail pharmacy of the co-payment amount to be collected

from the member.

[¶6] Express Scripts filed its original 2011 Maine corporate income tax

return in October 2012 and reported an overall Maine sales factor of 0.008036.3

The sales factor indicates the portion of a corporate taxpayer’s income that is subject to tax in 3

Maine, and is represented as “a fraction, the numerator of which is the total sales of the taxpayer in [Maine] during the tax period, and the denominator of which is the total sales of the taxpayer 5

In calculating the sales factor on the original 2011 Maine corporate income tax

return, Express Scripts apportioned receipts from the performance of its PBM

services on a market member basis.4

[¶7] ESI, Medco, and their affiliates filed their 2012 Maine corporate

income tax return in October 2013 and reported an overall Maine sales factor

of 0.002021. In calculating the sales factor applicable to its portion of the

unitary business, Medco apportioned receipts from the performance of its PBM

services on a market member basis, but ESI changed the method it used to

apportion receipts to calculate its sales factor, apportioning receipts from ESI’s

performance of PBM services on a market client basis.5 ESI made this change

even though its business operations and the applicable Maine statutes and rules

had not changed; and ESI did not notify Maine Revenue Service (MRS) that it

everywhere during the tax period.” 36 M.R.S. § 5211(14) (2023); see Kraft, 2020 ME 81, ¶¶ 1 n.2, 14, 235 A.3d 837.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Michael Good v. Town of Bar Harbor
2024 ME 48 (Supreme Judicial Court of Maine, 2024)

Cite This Page — Counsel Stack

Bluebook (online)
2023 ME 68, 304 A.3d 239, Counsel Stack Legal Research, https://law.counselstack.com/opinion/express-scripts-inc-et-al-me-2023.